# A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

> **NCT02956122** · PHASE2,PHASE3 · TERMINATED · sponsor: **Baxalta now part of Shire** · enrollment: 1 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **BIOLOGICAL:** GLASSIA
- **DRUG:** methylprednisolone or equivalent steroid
- **BIOLOGICAL:** Albumin

## Key facts

- **NCT ID:** NCT02956122
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-26
- **Primary completion:** 2018-05-03
- **Final completion:** 2018-05-03
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The decision to discontinue the study was based on business reasons.
- **Last updated:** 2021-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02956122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02956122, "A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02956122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*